Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P30536 (
PBS
)
9,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We studied the sensitivity of several human cancer cell strains (HeLa, HT1080,
SPC
-A1, and ACHN) and normal cell strains (MRC-5 and Wish) to mumps virus (MuV) S79, a live attenuated vaccine strain. These cells exhibited a differential sensitivity to infection with MuV, and the susceptible sequences were ACHN > HeLa > HT1080 >
SPC
-A1 > Wish > MRC-5. In experiments in vivo, nude mice with HT1080 fibrosarcoma xenografts were randomly divided into three groups for intratumoral treatment with MuVS79, UV-inactivated MuVS79, and
PBS
. At 10(7) PFU, live MuVS79 injection caused in 7 of 9 mice complete regression by day 15 while rapid tumor growth occurred in all 9 mice treated with
PBS
. Rapid tumor progression also occurred in all 8 mice treated with UV-inactivated virus; however, tumor growth was delayed in the logarithmic phase relative to the
PBS
-treated tumors.
...
PMID:Selective cytolysis of tumor cells by mumps virus S79. 1595 96
Octreotide is a somatostatin (SST) analogue currently used in the treatment of neuroendocrine tumors (NETs) with high binding affinity for the somatostatin receptor-2 (SSTR2) that is also overexpressed in non-small cell lung cancer cell (NSCLC). Alpha-particle-emitting astatine-211 (
211
At) is a promising radionuclide with appropriate physical and chemical properties for use in targeted anticancer therapies. To obtain an additional pharmacological agent for the treatment of NSCLC, we present the first investigation of the possible use of
211
At-labeled octreotide as a potential alpha-radionuclide therapeutic agent for NSCLC treatment.
211
At-
SPC
-octreotide exhibited observable higher uptake in lung, spleen, stomach and intestines than in other tissues. Through histological examination,
211
At-
SPC
-octreotide demonstrated much more lethal effect than control groups (
PBS
, octreotide and free
211
At). These promising preclinical results suggested that
211
At labeled octreotide deserved to be further developed as a new anticancer agent for NSCLC.
...
PMID:Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment. 2942 31
